NCCN Guidelines Insights : Non-Small Cell Lung Cancer, Version 5.2018
Copyright © 2018 by the National Comprehensive Cancer Network..
The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of the National Comprehensive Cancer Network : JNCCN - 16(2018), 7 vom: 30. Juli, Seite 807-821 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ettinger, David S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents, Immunological |
|---|
| Anmerkungen: |
Date Completed 21.10.2019 Date Revised 10.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.6004/jnccn.2018.0062 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM286473631 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM286473631 | ||
| 003 | DE-627 | ||
| 005 | 20231225051801.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.6004/jnccn.2018.0062 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0954.xml |
| 035 | |a (DE-627)NLM286473631 | ||
| 035 | |a (NLM)30006423 | ||
| 035 | |a (PII)jnccn_16_7_006 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ettinger, David S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NCCN Guidelines Insights |b Non-Small Cell Lung Cancer, Version 5.2018 |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2019 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 by the National Comprehensive Cancer Network. | ||
| 520 | |a The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Aisner, Dara L |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Douglas E |e verfasserin |4 aut | |
| 700 | 1 | |a Akerley, Wallace |e verfasserin |4 aut | |
| 700 | 1 | |a Bauman, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Joe Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chirieac, Lucian R |e verfasserin |4 aut | |
| 700 | 1 | |a D'Amico, Thomas A |e verfasserin |4 aut | |
| 700 | 1 | |a Dilling, Thomas J |e verfasserin |4 aut | |
| 700 | 1 | |a Dobelbower, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Govindan, Ramaswamy |e verfasserin |4 aut | |
| 700 | 1 | |a Gubens, Matthew A |e verfasserin |4 aut | |
| 700 | 1 | |a Hennon, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Horn, Leora |e verfasserin |4 aut | |
| 700 | 1 | |a Lackner, Rudy P |e verfasserin |4 aut | |
| 700 | 1 | |a Lanuti, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Leal, Ticiana A |e verfasserin |4 aut | |
| 700 | 1 | |a Lilenbaum, Rogerio |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jules |e verfasserin |4 aut | |
| 700 | 1 | |a Loo, Billy W |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Otterson, Gregory A |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Sandip P |e verfasserin |4 aut | |
| 700 | 1 | |a Reckamp, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Riely, Gregory J |e verfasserin |4 aut | |
| 700 | 1 | |a Schild, Steven E |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, Theresa A |e verfasserin |4 aut | |
| 700 | 1 | |a Stevenson, James |e verfasserin |4 aut | |
| 700 | 1 | |a Swanson, Scott J |e verfasserin |4 aut | |
| 700 | 1 | |a Tauer, Kurt |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Stephen C |e verfasserin |4 aut | |
| 700 | 1 | |a Gregory, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Miranda |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the National Comprehensive Cancer Network : JNCCN |d 2003 |g 16(2018), 7 vom: 30. Juli, Seite 807-821 |w (DE-627)NLM156397676 |x 1540-1413 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2018 |g number:7 |g day:30 |g month:07 |g pages:807-821 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.6004/jnccn.2018.0062 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2018 |e 7 |b 30 |c 07 |h 807-821 | ||